Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.

Svenningsson P, Johansson A, Nyholm D, Tsitsi P, Hansson F, Sonesson C, Tedroff J.

NPJ Parkinsons Dis. 2018 Dec 6;4:35. doi: 10.1038/s41531-018-0071-3. eCollection 2018.

2.

GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells.

Hertz E, Terenius L, Vukojević V, Svenningsson P.

Neuropharmacology. 2018 Nov 10. pii: S0028-3908(18)30846-3. doi: 10.1016/j.neuropharm.2018.11.009. [Epub ahead of print]

3.

Novel Xp21.1 deletion associated with unusual features in a large McLeod syndrome kindred.

Sveinsson O, Udd B, Svenningsson P, Gassner C, Engström C, Laffita-Mesa JM, Solders G, Hertegård S, Savitcheva I, Jung HH, Tolnay M, Frey BM, Paucar M.

Parkinsonism Relat Disord. 2018 Sep 26. pii: S1353-8020(18)30399-7. doi: 10.1016/j.parkreldis.2018.09.014. [Epub ahead of print] No abstract available.

PMID:
30305234
4.

Eye movements during reading in Parkinson's disease: A pilot study.

Waldthaler J, Tsitsi P, Seimyr GÖ, Benfatto MN, Svenningsson P.

Mov Disord. 2018 Oct;33(10):1661-1662. doi: 10.1002/mds.105. Epub 2018 Oct 8. No abstract available.

PMID:
30298615
5.

Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Fazio P, Paucar M, Svenningsson P, Varrone A.

Curr Neurol Neurosci Rep. 2018 Oct 5;18(12):85. doi: 10.1007/s11910-018-0890-y. Review.

6.

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging. 2018 Oct 1. doi: 10.1007/s00259-018-4161-6. [Epub ahead of print]

PMID:
30270409
7.

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome.

Björkhem I, Patra K, Boxer AL, Svenningsson P.

Front Neurol. 2018 Sep 7;9:756. doi: 10.3389/fneur.2018.00756. eCollection 2018.

8.

Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool.

Lazarevic V, Yang Y, Ivanova D, Fejtova A, Svenningsson P.

Neuropharmacology. 2018 Dec;143:38-48. doi: 10.1016/j.neuropharm.2018.09.021. Epub 2018 Sep 14.

PMID:
30222983
9.

Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations.

Paucar M, Pajak A, Freyer C, Bergendal Å, Döry M, Laffita-Mesa JM, Stranneheim H, Lagerstedt-Robinson K, Savitcheva I, Walker RH, Wedell A, Wredenberg A, Svenningsson P.

Neurology. 2018 Oct 9;91(15):710-712. doi: 10.1212/WNL.0000000000006320. Epub 2018 Sep 14. No abstract available.

10.

Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy.

Paucar M, Nennesmo I, Svenningsson P.

Front Genet. 2018 Aug 15;9:317. doi: 10.3389/fgene.2018.00317. eCollection 2018.

11.

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.

Siebzehnrübl FA, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, Achoui D, Gupta B, Steindler DA, Stephan M, Nguyen HP, Bonin M, Riess O, Bauer A, Aigner L, Couillard-Despres S, Paucar MA, Svenningsson P, Osmand A, Andreew A, Zabel C, Weiss A, Kuhn R, Moussaoui S, Blockx I, Van der Linden A, Cheong RY, Roybon L, Petersén Å, von Hörsten S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8765-E8774. doi: 10.1073/pnas.1807962115. Epub 2018 Aug 27.

12.

GLRA1 mutation and long-term follow-up of the first hyperekplexia family.

Paucar M, Waldthaler J, Svenningsson P.

Neurol Genet. 2018 Aug 7;4(4):e259. doi: 10.1212/NXG.0000000000000259. eCollection 2018 Aug. No abstract available.

13.

Dynamic lateral organization of opioid receptors (kappa, muwt and muN40D ) in the plasma membrane at the nanoscale level.

Rogacki MK, Golfetto O, Tobin SJ, Li T, Biswas S, Jorand R, Zhang H, Radoi V, Ming Y, Svenningsson P, Ganjali D, Wakefield DL, Sideris A, Small AR, Terenius L, Jovanović-Talisman T, Vukojević V.

Traffic. 2018 May 28. doi: 10.1111/tra.12582. [Epub ahead of print]

14.

Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.

Jaiteh M, Zeifman A, Saarinen M, Svenningsson P, Bréa J, Loza MI, Carlsson J.

J Med Chem. 2018 Jun 28;61(12):5269-5278. doi: 10.1021/acs.jmedchem.8b00204. Epub 2018 Jun 15.

PMID:
29792714
15.

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine.

Zhang X, Mantas I, Alvarsson A, Yoshitake T, Shariatgorji M, Pereira M, Nilsson A, Kehr J, Andrén PE, Millan MJ, Chergui K, Svenningsson P.

Front Pharmacol. 2018 Mar 1;9:166. doi: 10.3389/fphar.2018.00166. eCollection 2018.

16.

Novel Features and Abnormal Pattern of Cerebral Glucose Metabolism in Spinocerebellar Ataxia 19.

Paucar M, Bergendal Å, Gustavsson P, Nordenskjöld M, Laffita-Mesa J, Savitcheva I, Svenningsson P.

Cerebellum. 2018 Aug;17(4):465-476. doi: 10.1007/s12311-018-0927-4.

17.

Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A.

Mov Disord. 2018 Apr;33(4):592-599. doi: 10.1002/mds.27316. Epub 2018 Feb 13.

PMID:
29436751
18.

A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability.

Vallianatou T, Strittmatter N, Nilsson A, Shariatgorji M, Hamm G, Pereira M, Källback P, Svenningsson P, Karlgren M, Goodwin RJA, Andrén PE.

Neuroimage. 2018 May 15;172:808-816. doi: 10.1016/j.neuroimage.2018.01.013. Epub 2018 Jan 10.

PMID:
29329980
19.

Paroxysmal Kinesigenic Dyskinesia.

Paucar M, Malmgren H, Svenningsson P.

Tremor Other Hyperkinet Mov (N Y). 2017 Dec 12;7:529. doi: 10.7916/D8R79N2F. eCollection 2017.

20.

Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.

Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K.

Mol Psychiatry. 2018 Oct;23(10):2066-2077. doi: 10.1038/mp.2017.239. Epub 2017 Nov 21.

PMID:
29158578
21.

Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia.

Riggare S, Unruh KT, Sturr J, Domingos J, Stamford JA, Svenningsson P, Hägglund M.

Methods Inf Med. 2017 Oct 24;56(99):e123-e128. doi: 10.3414/ME16-02-0040. Epub 2017 Oct 24.

22.

Quantitative susceptibility mapping differentiates between parkinsonian disorders.

Sjöström H, Granberg T, Westman E, Svenningsson P.

Parkinsonism Relat Disord. 2017 Nov;44:51-57. doi: 10.1016/j.parkreldis.2017.08.029. Epub 2017 Sep 1.

PMID:
28886909
23.

Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.

Andréasson M, Brodin L, Laffita-Mesa JM, Svenningsson P.

J Parkinsons Dis. 2017;7(4):619-628. doi: 10.3233/JPD-171127.

PMID:
28759974
24.

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.

Neurology. 2017 Aug 22;89(8):845-853. doi: 10.1212/WNL.0000000000004264. Epub 2017 Jul 28.

25.

Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher's Disease Type 3.

Blume J, Beniaminov S, Kämpe Björkvall C, Machaczka M, Svenningsson P.

Front Neurol. 2017 Jun 22;8:295. doi: 10.3389/fneur.2017.00295. eCollection 2017.

26.

Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder.

Svenningsson P, Pålhagen S, Mathé AA.

Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102. eCollection 2017.

27.

Synaptic proteins in CSF relate to Parkinson's disease stage markers.

Bereczki E, Bogstedt A, Höglund K, Tsitsi P, Brodin L, Ballard C, Svenningsson P, Aarsland D.

NPJ Parkinsons Dis. 2017 Feb 8;3:7. doi: 10.1038/s41531-017-0008-2. eCollection 2017.

28.

Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease.

Leinartaité L, Svenningsson P.

Trends Pharmacol Sci. 2017 Aug;38(8):749-760. doi: 10.1016/j.tips.2017.05.006. Epub 2017 Jun 16. Review.

PMID:
28629580
29.

Patients with Parkinson's disease display a dopamine therapy related negative bias and an enlarged range in emotional responses to facial emotional stimuli.

Lundqvist D, Svärd J, Michelgård Palmquist Å, Fischer H, Svenningsson P.

Neuropsychology. 2017 Sep;31(6):605-612. doi: 10.1037/neu0000371. Epub 2017 Jun 5.

PMID:
28581310
30.

Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease.

Ran C, Wirdefeldt K, Brodin L, Ramezani M, Westerlund M, Xiang F, Anvret A, Willows T, Sydow O, Johansson A, Galter D, Svenningsson P, Belin AC.

Parkinsons Dis. 2017;2017:4020198. doi: 10.1155/2017/4020198. Epub 2017 May 2.

31.

Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.

Rame M, Caudal D, Schenker E, Svenningsson P, Spedding M, Jay TM, Godsil BP.

PLoS One. 2017 May 4;12(5):e0177036. doi: 10.1371/journal.pone.0177036. eCollection 2017.

32.

Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study.

Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, Wirdefeldt K.

Neurology. 2017 May 23;88(21):1996-2002. doi: 10.1212/WNL.0000000000003961. Epub 2017 Apr 26.

33.

Patients are doing it for themselves: A survey on disease-specific knowledge acquisition among people with Parkinson's disease in Sweden.

Riggare S, Höglund PJ, Hvitfeldt Forsberg H, Eftimovska E, Svenningsson P, Hägglund M.

Health Informatics J. 2017 Apr 1:1460458217704248. doi: 10.1177/1460458217704248. [Epub ahead of print]

PMID:
28434277
34.

Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia.

Devor A, Andreassen OA, Wang Y, Mäki-Marttunen T, Smeland OB, Fan CC, Schork AJ, Holland D, Thompson WK, Witoelar A, Chen CH, Desikan RS, McEvoy LK, Djurovic S, Greengard P, Svenningsson P, Einevoll GT, Dale AM.

Mol Psychiatry. 2017 Jun;22(6):792-801. doi: 10.1038/mp.2017.33. Epub 2017 Mar 28. Review.

35.

A SLC20A2 gene mutation carrier displaying ataxia and increased levels of cerebrospinal fluid phosphate.

Paucar M, Almqvist H, Jelic V, Hagman G, Jörneskog G, Holmin S, Björkhem I, Svenningsson P.

J Neurol Sci. 2017 Apr 15;375:245-247. doi: 10.1016/j.jns.2017.02.007. Epub 2017 Feb 4. No abstract available.

PMID:
28320140
36.

Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia - An autoradiography study.

Veldman ER, Svedberg MM, Svenningsson P, Lundberg J.

Eur Neuropsychopharmacol. 2017 May;27(5):504-514. doi: 10.1016/j.euroneuro.2017.02.011. Epub 2017 Mar 18.

PMID:
28318898
37.

First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.

Senek M, Hellström M, Albo J, Svenningsson P, Nyholm D.

Acta Neurol Scand. 2017 Dec;136(6):727-731. doi: 10.1111/ane.12756. Epub 2017 Mar 15.

PMID:
28299787
38.

Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.

Monnot C, Zhang X, Nikkhou-Aski S, Damberg P, Svenningsson P.

Exp Neurol. 2017 Jun;292:11-20. doi: 10.1016/j.expneurol.2017.02.014. Epub 2017 Feb 20.

39.

Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease.

Green H, Zhang X, Tiklova K, Volakakis N, Brodin L, Berg L, Greengard P, Perlmann T, Svenningsson P.

Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2735-2740. doi: 10.1073/pnas.1621218114. Epub 2017 Jan 30.

40.

Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.

Machaczka M, Paucar M, Björkvall CK, Smith NJC, Cox TM, Forsgren L, Svenningsson P.

Blood Cells Mol Dis. 2018 Feb;68:86-92. doi: 10.1016/j.bcmd.2016.10.011. Epub 2016 Oct 21.

PMID:
27789132
41.

CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease.

Remnestål J, Just D, Mitsios N, Fredolini C, Mulder J, Schwenk JM, Uhlén M, Kultima K, Ingelsson M, Kilander L, Lannfelt L, Svenningsson P, Nellgård B, Zetterberg H, Blennow K, Nilsson P, Häggmark-Månberg A.

Proteomics Clin Appl. 2016 Dec;10(12):1242-1253. doi: 10.1002/prca.201500150. Epub 2016 Oct 10.

42.

Cell- and region-specific expression of depression-related protein p11 (S100a10) in the brain.

Milosevic A, Liebmann T, Knudsen M, Schintu N, Svenningsson P, Greengard P.

J Comp Neurol. 2017 Mar 1;525(4):955-975. doi: 10.1002/cne.24113. Epub 2016 Oct 21.

43.

Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy.

Haack TB, Ignatius E, Calvo-Garrido J, Iuso A, Isohanni P, Maffezzini C, Lönnqvist T, Suomalainen A, Gorza M, Kremer LS, Graf E, Hartig M, Berutti R, Paucar M, Svenningsson P, Stranneheim H, Brandberg G, Wedell A, Kurian MA, Hayflick SA, Venco P, Tiranti V, Strom TM, Dichgans M, Horvath R, Holinski-Feder E, Freyer C, Meitinger T, Prokisch H, Senderek J, Wredenberg A, Carroll CJ, Klopstock T.

Am J Hum Genet. 2016 Sep 1;99(3):735-743. doi: 10.1016/j.ajhg.2016.06.026. Epub 2016 Aug 18.

44.

Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray.

Wang P, Li H, Barde S, Zhang MD, Sun J, Wang T, Zhang P, Luo H, Wang Y, Yang Y, Wang C, Svenningsson P, Theodorsson E, Hökfelt TG, Xu ZQ.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):E4726-35. doi: 10.1073/pnas.1609198113. Epub 2016 Jul 25.

45.

Progressive brain calcifications and signs in a family with the L9R mutation in the PDGFB gene.

Paucar M, Almqvist H, Saeed A, Bergendal G, Ygge J, Holmin S, Björkhem I, Svenningsson P.

Neurol Genet. 2016 Jul 6;2(4):e84. doi: 10.1212/NXG.0000000000000084. eCollection 2016 Aug.

46.

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.

Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF.

Mov Disord. 2016 Sep;31(9):1422-3. doi: 10.1002/mds.26734. Epub 2016 Jul 19. No abstract available.

PMID:
27431803
47.

Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance.

Bigio B, Mathé AA, Sousa VC, Zelli D, Svenningsson P, McEwen BS, Nasca C.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7906-11. doi: 10.1073/pnas.1603111113. Epub 2016 Jun 27.

48.

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.

Ran C, Brodin L, Forsgren L, Westerlund M, Ramezani M, Gellhaar S, Xiang F, Fardell C, Nissbrandt H, Söderkvist P, Puschmann A, Ygland E, Olson L, Willows T, Johansson A, Sydow O, Wirdefeldt K, Galter D, Svenningsson P, Belin AC.

Neurobiol Aging. 2016 Sep;45:212.e5-212.e11. doi: 10.1016/j.neurobiolaging.2016.04.022. Epub 2016 May 3.

49.

Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.

Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, Varrone A.

J Nucl Med. 2016 Oct;57(10):1529-1534. Epub 2016 May 26.

50.

PSP-CBS with Dopamine Deficiency in a Female with a FMR1 Premutation.

Paucar M, Beniaminov S, Paslawski W, Svenningsson P.

Cerebellum. 2016 Oct;15(5):636-40. doi: 10.1007/s12311-016-0793-x. Review.

PMID:
27230899

Supplemental Content

Loading ...
Support Center